Research programme: influenza virus vaccines - Johnson and Johnson/CureVac

Drug Profile

Research programme: influenza virus vaccines - Johnson and Johnson/CureVac

Alternative Names: RNActive® influenza vaccine - Johnson and Johnson/CureVac

Latest Information Update: 24 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CureVac
  • Developer CureVac; Johnson & Johnson
  • Class Influenza virus vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 12 Jun 2017 CureVac has patent protection for its mRNA based vaccines in the US and Europe
  • 03 Oct 2013 Preclinical trials in Influenza virus infections (prevention) in Germany (Intradermal)
  • 03 Oct 2013 Preclinical trials in Influenza virus infections (prevention) in Netherlands (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top